Preeclampsia Autoantibodies Drive Kidney Damage Through a Single MicroRNA, Study Finds

Preeclampsia has long been recognized as one of the most dangerous complications of pregnancy, a condition marked by soaring blood pressure and protein spilling into the urine after the twentieth week of gestation. Yet for all its clinical familiarity, the molecular chain of events that transforms a failing placental environment into lasting kidney damage has remained stubbornly opaque. A new study published in Reproductive Sciences now traces that chain with unusual precision, identifying a single microRNA molecule as the pivotal link between a circulating autoimmune antibody and the irreversible depletion of podocytes, the delicate filtration cells of the kidney. The findings, reported by a team led by researchers at Shanghai Fifth People’s Hospital of Fudan University, suggest that blocking this microRNA could simultaneously ease maternal hypertension and shield the kidney from permanent structural decline.

The research centers on the angiotensin II type 1 receptor agonistic autoantibody, abbreviated AT1-AA, a pathological antibody that has emerged over the past two decades as a central culprit in preeclampsia. Unlike ordinary antibodies, AT1-AA binds to and activates the angiotensin II type 1 receptor, the same molecular switch that the hormone angiotensin II uses to constrict blood vessels and raise blood pressure. Women with preeclampsia frequently carry this autoantibody in their circulation, and laboratory models have shown that infusing it into pregnant animals reproduces many of the classic features of the disease, including severe hypertension, albuminuria, and injury to the glomerular filtration barrier. What has been less clear is how AT1-AA inflicts damage on podocytes, the specialized epithelial cells whose interdigitating foot processes form the final, finest sieve of the kidney filter.

Podocytes are notoriously vulnerable cells. Once lost, they are not readily replaced, and their depletion predisposes patients to chronic kidney disease long after the pregnancy has ended. Epidemiological studies have repeatedly shown that women with a history of preeclampsia carry a heightened lifetime risk of renal disease, making the search for protective mechanisms more than an academic exercise. The authors of the new study focused on premature cellular senescence, the process by which injured cells permanently exit the cell cycle and begin secreting a cocktail of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. Senescence had been implicated in podocyte loss before, but the specific preeclamptic factors that trigger it had not been pinned down.

To find them, the team began with human data. They interrogated publicly available clinical transcriptomic datasets from patients with preeclampsia, then validated their computational findings using urine specimens collected from preeclamptic women. The screening pointed consistently to one microRNA: miR-122-5p, a short regulatory RNA molecule that was significantly upregulated in preeclampsia. MicroRNAs do not encode proteins; instead, they act as post-transcriptional silencers, binding to complementary sequences in messenger RNAs and preventing them from being translated into functional proteins. MiR-122-5p, best known as a liver-enriched microRNA, had previously been linked to renal fibrosis and to inflammatory macrophage activation in lupus nephritis through its suppression of the FOXO family of transcription factors, which made it a compelling candidate in the kidney context.

The candidate mechanism crystallized around FOXO3, a forkhead transcription factor with a well-established role in antioxidant defense. FOXO3 drives the expression of SOD2, manganese superoxide dismutase, the enzyme responsible for detoxifying superoxide radicals generated inside mitochondria. When FOXO3 activity falls, mitochondrial reactive oxygen species accumulate unchecked, and the resulting oxidative stress can push cells into senescence. Using dual-luciferase reporter assays in cultured human podocytes, the researchers confirmed that miR-122-5p directly targets the FOXO3 messenger RNA, repressing the antioxidant axis at its source. The cascade that followed was striking: AT1-AA exposure raised miR-122-5p, miR-122-5p silenced FOXO3, FOXO3 silencing depleted SOD2, and mitochondrial reactive oxygen species surged, triggering the nuclear accumulation of p21, a canonical senescence marker, along with the full SASP inflammatory program.

In cell culture, the consequences were clear enough, but the decisive test came in a living system. The investigators used a pregnant mouse model in which AT1-AA was infused to replicate preeclampsia. The animals developed the expected phenotype: severe hypertension, albuminuria, and, on electron microscopy, effacement of podocyte foot processes, the ultrastructural hallmark of a failing filtration barrier. Kidney tissue from these animals showed podocyte-specific senescence, with nuclear p21 accumulation and elevated SASP cytokines concentrated in the glomeruli. The pathology mapped neatly onto the molecular cascade defined in vitro, tying the autoantibody to senescence through the microRNA bridge and confirming that the same regulatory circuit operates in the intact pregnant organism.

The therapeutic implication was equally direct. If miR-122-5p sits at the bottleneck of the pathway, then neutralizing it should relieve the damage from the top down. The team administered AntagomiR-122-5p, a chemically modified antisense inhibitor designed to sequester and degrade the microRNA, systemically to the AT1-AA-exposed pregnant mice. The results were notable on two fronts. First, the inhibitor blunted the rise in maternal systolic blood pressure, addressing the cardiovascular dimension of the disease. Second, and perhaps more importantly, it conferred direct cytoprotection to the glomerular filtration barrier itself: glomerular senescence receded, local inflammatory cytokine production was suppressed, and podocyte ultrastructure was substantially restored on microscopic examination. A single intervention thus produced what the authors describe as dual therapeutic benefits, targeting both the maternal hypertensive phenotype and the renal structural injury that underlies long-term kidney risk.

The significance of this work lies partly in its unification of previously separate threads of preeclampsia biology. The autoantibody, oxidative stress, senescence, and proteinuria have each been studied in isolation for years, but the new findings place them on a single continuous pathway in which a clinically detectable microRNA mediates the transmission of autoimmune signaling into permanent cellular aging. The identification of miR-122-5p as a circulating, measurable, and pharmacologically targetable molecule also raises the prospect of biomarker-guided therapy: levels of the microRNA in maternal urine or plasma could, in principle, identify patients in whom the podocyte-injury pathway is active, well before proteinuria becomes clinically apparent. Such early detection would be valuable precisely because podocyte loss is irreversible, and interventions delivered after structural damage has accumulated are inherently limited.

Considerable work remains before the findings translate to the clinic. The study relied on an antibody-infused mouse model, which reproduces key features of preeclampsia but does not capture every facet of the human disease, and antagomiR technologies face established delivery and safety hurdles in pregnant populations. Nevertheless, the study provides one of the most mechanistically complete accounts to date of how a preeclamptic factor drives podocyte senescence, and it does so through a pathway that is simultaneously druggable and measurable. For the millions of women affected by preeclampsia each year, and for the nephrologists who manage their long-term kidney risk years after delivery, the demonstration that a single microRNA stands between autoantibody signaling and permanent filtration-barrier damage offers a genuinely new therapeutic horizon, one in which protecting the kidney during pregnancy may become an explicit and achievable goal rather than an afterthought.

Subject of Research: MicroRNA-122-5p-mediated podocyte senescence and proteinuria induced by angiotensin II type 1 receptor autoantibodies in preeclampsia.

Article Title: MicroRNA-122-5p Targets FOXO3 to Mediate Podocyte Senescence and Proteinuria Induced by Angiotensin II Type 1 Receptor Autoantibodies in Preeclampsia

Article References: Xu, G., Yang, Z., Liu, Y., Zong, C., Zhong, X., Zhou, Y., Zhao, D., Zhang, C., Zhang, L., Yang, L., & Niu, J. (2026). MicroRNA-122-5p Targets FOXO3 to Mediate Podocyte Senescence and Proteinuria Induced by Angiotensin II Type 1 Receptor Autoantibodies in Preeclampsia. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02198-1

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02198-1

Keywords: preeclampsia, podocyte senescence, miR-122-5p, FOXO3, SOD2, AT1-AA, proteinuria, mitochondrial reactive oxygen species, AntagomiR-122-5p, hypertension, kidney disease, Reproductive Sciences